NCT03331250

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

Detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific disease but it has been approved for other uses. In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE. Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules

Conditions

• Angiosarcoma
• Epithelioid Hemangioendothelioma

Interventions

Type	Name	Description
DRUG	Eribulin	It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die

Timeline

• Start date: 2018-01-18
• Primary completion: 2023-07-21
• Completion: 2026-02-01
• First posted: 2017-11-06
• Last updated: 2025-12-23
• Results posted: 2024-11-08

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study